Royalty Pharma PLC

Return on Assets, %

10.2

-2.7

Net income margin, %

120.3

2.8

EBITDA margin, %

102.8

10.8

Debt to Equity, %

94

19.2

Intangible assets and goodwill, %

0

3.6

Revenue CAGR 3Y, %

3.5

8.5

Total Equity change 1Y, %

15.9

0

Revenue Y, % chg

5.2

0.5

P/E

11.1

22.7

P/BV

1.9

1.5

P/S

7.1

2.3

EV/S

10.7

2.4

EV/EBITDA

16.9

7.4

Average Analyst recommendation

Buy

Buy

Average upside forecasts, %

55.9

51.3

Forward P/E

7.3

15.6

Dividend Yield, %

2.8

1.7

Forward Dividend Yield, %

3.2

0.2

Expected dividend per share

0.9

0

Payout Ratio, %

31.5

30.3

Dividend Ex Date

2024-02-15